Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study
Authors:
- Min H KangMKMin H Kang
- Judith G VillablancaJVJudith G Villablanca
- Julia L Glade BenderJBJulia L Glade Bender
- Katherine K MatthayKMKatherine K Matthay
- Susan GroshenSGSusan Groshen
- Richard SpostoRSRichard Sposto
- Scarlett CzarneckiSCScarlett Czarnecki
- Matthew M AmesMAMatthew M Ames
- C Patrick ReynoldsCRC Patrick Reynolds
- Araz MarachelianAMAraz Marachelian
- Barry J MaurerBMBarry J Maurer
Open Access
- 23 April 2014
- journal article
- case report
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 256
Abstract
Patients with relapsed/refractory stage 4 high-risk neuroblastoma were enrolled on a phase I study (NANT2004-03) of intravenous fenretinide emulsion. Pharmacokinetic samples were collected during and after the infusion, and the levels were measured using an HPLC system. A likely case of a fatal drug interaction between fenretinide, ceftriaxone, and acetaminophen is described, including the pharmacokinetics of fenretinide, laboratory data, and post-mortem autopsy in a pediatric neuroblastoma patient treated on this study. On Day 4 of a scheduled 5-day-infusion of intravenous fenretinide, the patient developed a fever, acetaminophen was started, ceftriaxone initiated for possible bacteremia, and fenretinide level doubled from 56 to 110 μM. Over the next three days, although blood cultures remained negative, the patient’s condition deteriorated rapidly. Acute liver failure was diagnosed on Day 7, and the patient expired on Day 20 of fulminant hepatic failure with associated renal, cardiac, and hemorrhagic/coagulation toxicities. Autopsy showed extensive hemorrhagic necrosis of the liver, marked bile duct proliferation, and abundant hemosiderin, consistent with cholestasis and drug toxicity. After extensive review of patient data, the clinical course, and the literature, we conclude that observed hepatic toxicity was likely due to a drug interaction between fenretinide and concomitant ceftriaxone and acetaminophen. None of the other 16 patients treated on this study experienced significant hepatic toxicity. Although the prevalence of cholestasis with ceftriaxone usage is relatively high, the potential drug interaction with these concomitant medications has not been previously reported. Concomitant use of fenretinide, ceftriaxone, and acetaminophen should be avoided.Keywords
This publication has 21 references indexed in Scilit:
- Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortiumPediatric Blood & Cancer, 2013
- Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group StudyJournal of Clinical Oncology, 2011
- Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology GroupClinical Cancer Research, 2011
- Fenretinide metabolism in humans and mice: utilizing pharmacological modulation of its metabolic pathway to increase systemic exposureBritish Journal of Pharmacology, 2011
- Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709)Journal of Clinical Oncology, 2006
- Ceftriaxone‐associated biliary sludge and pseudocholelithiasis during childhood: A prospective studyPediatrics International, 2004
- N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytesLeukemia, 2002
- Biliary SludgeAnnals of Internal Medicine, 1999
- Etiology and outcome for 295 patients with acute liver failure in the united statesLiver Transplantation and Surgery, 1999
- Gall‐bladder sludge: Lessons from ceftriaxoneJournal of Gastroenterology and Hepatology, 1992